Compare Gilead Sciences, Inc. (GILD) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Gilead Sciences, Inc. trades at $148.72 (market cap $182.40B), while YieldMax NVDA Option Income Strategy ETF trades at $12.63 (market cap $1.45B). The key difference: Gilead Sciences, Inc. is far larger — about 125.8× YieldMax NVDA Option Income Strategy ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while YieldMax NVDA Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and YieldMax NVDA Option Income Strategy ETF for 43 Days on average.
| GILD | NVDY | |
|---|---|---|
Market Cap | $182.40B | $1.45B |
Volume | 4,469,821 | 1,943,739 |
Sector | Health | Income / Options Overlay |
52-Week High | $155.80 | $17.21 |
52-Week Low | $116.74 | $11.58 |
Typical Hold Time | 111 Days | 43 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.64, down 2.84% on the day amid a bearish technical signal. The fund generates income through options on NVIDIA stock but faces headwinds from declining volatility, which caps upside participation and has led to recent analyst downgrades. Weekly dividend distributions continue, but concerns over net asset value erosion persist.
The outlook for NVDY is cautious, as its high distribution yield comes with structural limitations on capital appreciation. Investment opportunity lies in income generation for risk-tolerant investors, but risks include NAV erosion and dependency on NVIDIA's volatility. Analyst sentiment has shifted to hold, reflecting diminished attractiveness amid lower option premiums.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
